Cargando…

Low-dose naloxone provides an abuse-deterrent effect to buprenorphine

In developmental research, plasma buprenorphine concentrations comparable to a 2 mg buprenorphine–naloxone (BN) sublingual tablet have been achieved with a 0.75 mg dose of BN buccal film, a small, bioerodible polymer film for application to mucosal membranes. This was a randomized, double-blind, pla...

Descripción completa

Detalles Bibliográficos
Autores principales:	Webster, Lynn R, Smith, Michael D, Unal, Cemal, Finn, Andrew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4639562/ https://www.ncbi.nlm.nih.gov/pubmed/26604818 http://dx.doi.org/10.2147/JPR.S90780

Ejemplares similares

Dancing with Deterrents: Understanding the Role of Abuse‐Deterrent Opioid Formulations and Naloxone in Managing Cancer Pain
por: Mitchell, Megan T.
Publicado: (2019)

Oxycodone/Naloxone: Role in Chronic Pain Management, Opioid-Induced Constipation, and Abuse Deterrence
por: DePriest, Anne Z., et al.
Publicado: (2014)

Successful Buprenorphine/Naloxone Low-dose Induction in Pregnancy: A Case Report
por: Coish, Rebecca, et al.
Publicado: (2023)

Comparison of Buprenorphine and Buprenorphine/naloxone in Detoxification of Opioid-dependent Men
por: Ziaaddini, Hassan, et al.
Publicado: (2018)

Reconsidering the Usefulness of Adding Naloxone to Buprenorphine
por: Blazes, Christopher K., et al.
Publicado: (2020)

Abuse of Synthetic Cannabinoids and Cathinones in a Patient on Buprenorphine-Naloxone Treatment: A Case Report
por: Awasthi, Harshal
Publicado: (2023)

Oxybutynin treatment for buprenorphine-naloxone-induced hyperhidrosis
por: McCormack, Lindsay, et al.
Publicado: (2021)

Disparities in Emergency Department Naloxone and Buprenorphine Initiation
por: Papp, Joan, et al.
Publicado: (2023)

Buprenorphine‐naloxone, buprenorphine, and methadone throughout pregnancy in maternal opioid use disorder
por: Kanervo, Minna M., et al.
Publicado: (2022)

Yoga as an Adjunctive Intervention to Medication-Assisted Treatment with Buprenorphine+Naloxone
por: Lander, Laura, et al.
Publicado: (2017)

Patient Satisfaction with Primary Care Office-Based Buprenorphine/Naloxone Treatment
por: Barry, Declan T., et al.
Publicado: (2007)

A Randomized, Double-Blind, Double-Dummy Study to Evaluate the Intranasal Human Abuse Potential and Pharmacokinetics of a Novel Extended-Release Abuse-Deterrent Formulation of Oxycodone
por: Webster, Lynn R., et al.
Publicado: (2016)

Observational study of the safety of buprenorphine+naloxone in pregnancy in a rural and remote population
por: Jumah, Naana Afua, et al.
Publicado: (2016)

Successful Management of Kratom Use Disorder With Buprenorphine and Naloxone
por: Arhin, Martin, et al.
Publicado: (2023)

A retrospective evaluation of patients switched from buprenorphine (subutex) to the buprenorphine/naloxone combination (suboxone)
por: Simojoki, Kaarlo, et al.
Publicado: (2008)

Relapse rates among veterans on maintenance doses of combination buprenorphine and naloxone for opioid use disorder
por: Binger, Katie J., et al.
Publicado: (2020)

A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Intranasal Human Abuse Potential Study of Oxycodone ARIR, a Novel, Immediate-Release, Abuse-Deterrent Formulation
por: Webster, Lynn R, et al.
Publicado: (2019)

New developments in the management of opioid dependence: focus on sublingual buprenorphine–naloxone
por: Soyka, Michael
Publicado: (2015)

Abuse Potential with Oral Route of Administration of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users
por: Darwish, Mona, et al.
Publicado: (2017)

Budgetary impact analysis of buprenorphine-naloxone combination (Suboxone(®)) in Spain
por: Martinez-Raga, Jose, et al.
Publicado: (2012)

Utilizing buprenorphine–naloxone to treat illicit and prescription-opioid dependence
por: Mauger, Sofie, et al.
Publicado: (2014)

Neonatal outcomes following in utero exposure to buprenorphine/naloxone or methadone
por: Gawronski, Kristen M, et al.
Publicado: (2014)

Sexual dysfunction in men on buprenorphine – naloxone-based substitution therapy
por: Mattoo, Surendra K., et al.
Publicado: (2020)

Prenatal Buprenorphine/Naloxone or Methadone Use on Neonatal Outcomes in Michigan
por: Goshgarian, Gregory, et al.
Publicado: (2022)

Opioid-induced constipation: rationale for the role of norbuprenorphine in buprenorphine-treated individuals
por: Webster, Lynn R, et al.
Publicado: (2016)

Relative Oral Bioavailability of an Abuse-Deterrent, Immediate-Release Formulation of Oxycodone, Oxycodone ARIR in a Randomized Study
por: Webster, Lynn R., et al.
Publicado: (2019)

Evaluation of drug-drug interaction between daclatasvir and methadone or buprenorphine/naloxone
por: Garimella, Tushar, et al.
Publicado: (2014)

Buprenorphine/naloxone addiction in a pharmacist as a result of migraine self-treatment
por: Norton, Merrill, et al.
Publicado: (2016)

Microdose induction of buprenorphine-naloxone in a patient using high dose methadone: A case report
por: Menard, Shannon, et al.
Publicado: (2021)

Evaluation of the Relative Intranasal Abuse Potential of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users
por: Bond, Mary, et al.
Publicado: (2018)

A Comparison of Buprenorphine + Naloxone to Buprenorphine and Methadone in the Treatment of Opioid Dependence during Pregnancy: Maternal and Neonatal Outcomes
por: Lund, Ingunn O., et al.
Publicado: (2013)

Safety and Efficacy of Buprenorphine-Naloxone in Pregnancy: A Systematic Review of the Literature
por: Ordean, Alice, et al.
Publicado: (2023)

BUPRENORPHINE ABUSE IN INDIA : AN UPDATE
por: Sharma, Yogesh, et al.
Publicado: (1999)

Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) vs Extended-Release Morphine Administered Intranasally in Nondependent Recreational Opioid Users
por: Webster, Lynn R., et al.
Publicado: (2017)

Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) versus Extended-Release Morphine Administered Orally in Nondependent Recreational Opioid Users
por: Smith, Michael D., et al.
Publicado: (2017)

823 Evaluation of Drug-Drug Interaction between Asunaprevir and Methadone or Buprenorphine/Naloxone
por: Garimella, Tushar, et al.
Publicado: (2014)

Evaluation of buprenorphine/naloxone dose and use of sedating supportive medication on treatment outcomes in veterans with opioid use disorder
por: Kapuganti, Amber, et al.
Publicado: (2018)

An overview of abuse-deterrent opioids and recommendations for practical patient care
por: Adler, Jeremy A, et al.
Publicado: (2018)

Comment on “A Comparison of Buprenorphine + Naloxone to Buprenorphine and Methadone in the Treatment of Opioid Dependence During Pregnancy: Maternal and Neonatal Outcomes”
por: Newman, Robert G., et al.
Publicado: (2013)

The effect of an abuse‐deterrent opioid formulation (OxyContin) on opioid abuse‐related outcomes in the postmarketing setting
por: Coplan, PM, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_2h11ppncjr3ua8h5i3648qlerk